DE60129860D1 - Rekombinante rsv-virus-expressionssysteme und -impfstoffe - Google Patents

Rekombinante rsv-virus-expressionssysteme und -impfstoffe

Info

Publication number
DE60129860D1
DE60129860D1 DE60129860T DE60129860T DE60129860D1 DE 60129860 D1 DE60129860 D1 DE 60129860D1 DE 60129860 T DE60129860 T DE 60129860T DE 60129860 T DE60129860 T DE 60129860T DE 60129860 D1 DE60129860 D1 DE 60129860D1
Authority
DE
Germany
Prior art keywords
vaccinates
expression systems
virus expression
recombinant rsv
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60129860T
Other languages
English (en)
Other versions
DE60129860T2 (de
Inventor
Hong Jin
Roderick Tang
Shengqiang Li
Martin Bryant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Vaccines Inc
Original Assignee
MedImmune Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Vaccines Inc filed Critical MedImmune Vaccines Inc
Application granted granted Critical
Publication of DE60129860D1 publication Critical patent/DE60129860D1/de
Publication of DE60129860T2 publication Critical patent/DE60129860T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE60129860T 2000-11-28 2001-11-28 Rekombinante rsv-virus-expressionssysteme und -impfstoffe Expired - Lifetime DE60129860T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72441600A 2000-11-28 2000-11-28
US724416 2000-11-28
PCT/US2001/044819 WO2002044334A2 (en) 2000-11-28 2001-11-28 Recombinant rsv virus expression systems and vaccines

Publications (2)

Publication Number Publication Date
DE60129860D1 true DE60129860D1 (de) 2007-09-20
DE60129860T2 DE60129860T2 (de) 2008-04-24

Family

ID=24910360

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60129860T Expired - Lifetime DE60129860T2 (de) 2000-11-28 2001-11-28 Rekombinante rsv-virus-expressionssysteme und -impfstoffe

Country Status (11)

Country Link
EP (2) EP1920783A1 (de)
JP (2) JP4268407B2 (de)
AT (1) ATE369148T1 (de)
AU (2) AU3652202A (de)
CA (2) CA2430115C (de)
CY (1) CY1107786T1 (de)
DE (1) DE60129860T2 (de)
DK (1) DK1480671T3 (de)
ES (1) ES2291370T3 (de)
PT (1) PT1480671E (de)
WO (1) WO2002044334A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430115C (en) * 2000-11-28 2013-02-26 Aviron, Inc. Recombinant rsv virus expression systems and vaccines
IL157003A0 (en) 2001-01-19 2004-02-08 Vironovative Bv A virus causing respiratory tract illness in susceptible mammals
EP1441762A1 (de) 2001-09-28 2004-08-04 University Of South Florida Rsv genexpressions impstoff
CN1646684B (zh) 2002-02-21 2010-10-06 免疫医疗疫苗公司 重组副流感病毒表达系统以及包含源自间质肺病毒的异种抗原的疫苗
WO2004028478A2 (en) * 2002-09-27 2004-04-08 Medimmune Vaccines, Inc. Functional mutations in respiratory syncytial virus
DE602004027362D1 (de) 2003-03-28 2010-07-08 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
CN101410519B (zh) * 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
WO2012167139A2 (en) * 2011-06-01 2012-12-06 The Board Of Regents For Oklahoma State University Engineered respiratory syncytial viruses with control of cell-to-cell virus transmission for enhanced safety of live virus vaccines
EP2718445B1 (de) * 2011-06-08 2023-08-09 Vishwas Joshi Säugetierexpressionssystem mit zwei plasmiden zur herstellung rekombinanter proteine und viren
JP6132420B2 (ja) * 2011-10-25 2017-05-24 国立大学法人岐阜大学 変異狂犬病ウイルス合成・増殖方法、並びに狂犬病ワクチン製剤
EP3386539A1 (de) * 2015-12-11 2018-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rekombinante respiratorische syncytialvirusstämme mit mutationen im m2-2 orf, die eine reihe von dämpfungsphänotypen bereitstellen
CN115725657A (zh) * 2022-09-16 2023-03-03 中国科学院广州生物医药与健康研究院 一种节段化的水泡性口炎病毒载体及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
AU727923B2 (en) * 1995-09-27 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of infectious respiratory syncytial virus from cloned nucleotide sequences
BRPI9710363B8 (pt) * 1996-07-15 2021-07-06 Us Gov Health & Human Serv partìcula de vìrus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vìrus sincicial respiratório recombinante (rsv) infeccioso.
AU5918100A (en) * 1999-07-09 2001-01-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
CA2430115C (en) * 2000-11-28 2013-02-26 Aviron, Inc. Recombinant rsv virus expression systems and vaccines

Also Published As

Publication number Publication date
DE60129860T2 (de) 2008-04-24
EP1480671B1 (de) 2007-08-08
WO2002044334A2 (en) 2002-06-06
PT1480671E (pt) 2007-11-20
EP1920783A1 (de) 2008-05-14
CA2797703A1 (en) 2002-06-06
EP1480671A4 (de) 2005-06-01
JP2004534514A (ja) 2004-11-18
CY1107786T1 (el) 2013-06-19
JP2009028041A (ja) 2009-02-12
JP4268407B2 (ja) 2009-05-27
CA2430115C (en) 2013-02-26
DK1480671T3 (da) 2007-12-10
AU3652202A (en) 2002-06-11
ATE369148T1 (de) 2007-08-15
ES2291370T3 (es) 2008-03-01
EP1480671A2 (de) 2004-12-01
WO2002044334A3 (en) 2004-08-26
AU2002236522B2 (en) 2007-10-25
CA2430115A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
CY1107786T1 (el) Συστηματα εκφρασεως και εμβολια ανασυνδυασμενου ιου rsv
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
GT200600262A (es) Uso de la sangliferina en el hcv (virus de la hepatitis "c")
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
EA200300810A1 (ru) Вирус, вызывающий заболевание дыхательных путей у восприимчивых млекопитающих
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
ATE417097T1 (de) Rekombinantes respiratorische synzytialvirus expressionssystem und impfstoffe
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
DK1086207T3 (da) Hidtil ukendte fremgangsmåder og inteferon-deficiente substrater til opformering af vira
AU2002364730A8 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
BR0305259A (pt) Inibidores de hcv ns5b polimerase
WO2007081517A8 (en) Anti-viral compounds
WO2007076035A3 (en) Anti-viral compounds
ATE405647T1 (de) Rekombinantes gelatin in impstoffen
WO2003053344A3 (en) Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
WO2003055896A3 (en) Anti-viral 7-deaza l-nucleosides
DE602004030343D1 (de) Hcv-vakzin
BR0108499A (pt) Agente terapêutico para hepatite c
WO2002092006A3 (en) Nucleic acid-based compounds and methods of use thereof
DE60130998D1 (de) Ribavirin-enthaltende vakzine
MXPA03000061A (es) Manipulacion de virus de arn encadenados negativos mediante redisposicion de sus genes y usos de los mismos.
WO2002072803A3 (en) Subgenomic replicons of the flavivirus dengue
WO2002094844A3 (en) Antiviral nucleosides

Legal Events

Date Code Title Description
8364 No opposition during term of opposition